Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Safety And Efficacy Of Darunavir (tmc114) With Low-dose Ritonavir In Treatment-experienced Patients: 24-week Results Of Power 3
Author: Molina J.-M.
Cohen C.
Katlama C.
Grinsztejn B.
Timerman A.
Pedro R.D.J.
Vangeneugden T.
Miralles D.
Meyer S.D.
Parys W.
Lefebvre E.
Abstract: OBJECTIVE: In POWER 1 and POWER 2, darunavir (TMC114) with low-dose ritonavir (darunavir/r) demonstrated greater efficacy versus control protease inhibitors (PIs). To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed. METHODS: Treatment-experienced HIV-1-infected patients received darunavir/r at a dose of 600/100 mg twice daily plus an optimized background regimen. The primary intent-to-treat analysis was the proportion of patients with an HIV-1 RNA reduction ≥1 log10 at week 24. RESULTS: Three hundred twenty-seven patients were treated; the baseline mean HIV-1 RNA was 4.6 log10 copies/mL, and the median CD4 count was 115 cells/mm (median primary PI mutations = 3, PI resistance-associated mutations = 9). Two hundred forty-six patients reached week 24 by the cutoff date and were included in the efficacy analysis: 65% and 40% achieved HIV-1 RNA reductions of ≥1 log10 and <50 copies/mL, respectively, at week 24. The mean CD4 count increase was 80 cells/mm. The most common adverse events (AEs) were diarrhea (14%), nasopharyngitis (11%), and nausea (10%). Nine (3%) patients discontinued treatment because of AEs or HIV-1-related events. Six treatment-unrelated deaths (2%) were reported. CONCLUSIONS: These results corroborate POWER 1 and POWER 2. In this larger set of treatment-experienced patients, darunavir/r at a dose of 600/100 mg twice daily provided substantial virologic and immunologic responses and was generally safe and well tolerated. © 2007 Lippincott Williams & Wilkins, Inc.
Rights: fechado
Identifier DOI: 10.1097/QAI.0b013e3181359cfb
Date Issue: 2007
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.